Labcorp Holdings CapEx decreased by 2.3% to $121.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.0%, from $126.00M to $121.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows relatively stable performance with a 0.8% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $97.20M | $117.80M | $111.10M | $117.20M | $143.30M | $69.70M | $99.10M | $78.20M | $103.30M | $104.90M | $167.20M | $133.80M | $128.20M | $115.80M | $112.10M | $126.00M | $77.90M | $106.70M | $123.90M | $121.00M |
| QoQ Change | — | +21.2% | -5.7% | +5.5% | +22.3% | -51.4% | +42.2% | -21.1% | +32.1% | +1.5% | +59.4% | -20.0% | -4.2% | -9.7% | -3.2% | +12.4% | -38.2% | +37.0% | +16.1% | -2.3% |
| YoY Change | — | — | — | — | +47.4% | -40.8% | -10.8% | -33.3% | -27.9% | +50.5% | +68.7% | +71.1% | +24.1% | +10.4% | -33.0% | -5.8% | -39.2% | -7.9% | +10.5% | -4.0% |